Reaction
Injection Site Oedema reporting signals
As of the last recalculation, Injection Site Oedema appears in 1,684 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is PEGVALIASE-PQPZ (PRR 25.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pegvaliase-Pqpz | 17 | 25.8 | 25.9 |
| Fremanezumab-Vfrm | 20 | 21.8 | 21.8 |
| Octreotide Acetate | 42 | 17.4 | 17.4 |
| Onabotulinumtoxina | 82 | 13.8 | 13.8 |
| Cabotegravir | 8 | 12.3 | 12.3 |
| Botulinum Toxin Type A | 11 | 11.0 | 11.0 |
| Ixekizumab | 32 | 10.9 | 10.9 |
| Iohexol | 7 | 10.5 | 10.5 |
| Candesartan Cilexetil | 21 | 10.0 | 10.0 |
| Romosozumab-Aqqg | 10 | 9.2 | 9.2 |
| Iron Sucrose | 7 | 9.1 | 9.1 |
| Glatiramer Acetate | 42 | 8.9 | 8.9 |
| Naltrexone | 21 | 8.5 | 8.5 |
| Anakinra | 10 | 7.5 | 7.5 |
| Peginterferon Beta-1A | 7 | 6.6 | 6.6 |
| Desoximetasone | 10 | 6.5 | 6.5 |
| Dexlansoprazole | 21 | 6.3 | 6.3 |
| Asfotase Alfa | 5 | 6.2 | 6.2 |
| Alteplase | 6 | 5.0 | 5.0 |
| Treprostinil | 48 | 4.8 | 4.8 |
| Sarilumab | 10 | 4.7 | 4.7 |
| Bimekizumab | 7 | 4.1 | 4.1 |
| Leuprolide Acetate | 25 | 4.0 | 4.0 |
| Buprenorphine | 22 | 3.0 | 3.0 |
| Alirocumab | 6 | 3.0 | 3.0 |
| Galcanezumab-Gnlm | 7 | 2.8 | 2.8 |
| Paliperidone Palmitate | 7 | 2.7 | 2.7 |
| Dornase Alfa | 4 | 2.5 | 2.5 |
| Dupilumab | 66 | 1.7 | 1.7 |